Next 10 |
2024-04-23 13:32:13 ET More on Sanofi Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi succeeds in late-stage trial for ...
2024-04-23 13:21:30 ET More on Alto Neuroscience Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS Disorders Stifel, Baird, Jefferies bullish on Alto Neuroscience, cite upcoming data Alto Neuroscience stock rallies 35% following upsized IPO ...
2024-04-23 09:44:51 ET More on Sanofi Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi reportedly settles 4K Zantac case...
2024-04-22 12:03:46 ET More on GSK, Sanofi, etc. GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) GSK shingles vaccine shown 82% ...
2024-04-19 14:48:33 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among ...
2024-04-17 08:48:28 ET More on IGM Biosciences IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points IGM Biosciences GAAP EPS of -$1.01 beats by $0.08, revenue of $0.7M misses by $0.07M RBC Capital upgrades IGM Biosciences to outperform ...
2024-04-17 01:50:40 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...
2024-04-12 12:02:53 ET More on AbbVie, Biogen, etc. AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% Novo Nordisk: The Moat Won't Last Forever AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision No link between weight...
2024-04-12 07:05:43 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk: The Moat Won't Last Forever Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Roche, Eli Lilly gain ...
News, Short Squeeze, Breakout and More Instantly...
As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...
Tuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in...
Novartis AG (NYSE:NVS) released data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta ...